Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986712 · ClinicalTrials.gov registry record
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
A clinical trial of Melanoma, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- Completed
- Registry status
- 50
- Enrollment target
- 4
- Study locations
NCT01986712: Completed study of Melanoma, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
NCT01986712 is a study of Melanoma that has completed, run by St. Luke's Hospital and Health Network, Pennsylvania. The registered enrollment target is 50 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01986712, a study of Melanoma, has completed, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
Primary Outcome
To evaluate compliance with administration of standard HDI versus PEG IFN for patients with surgically resected melanoma in need of adjuvant therapy
Conditions Studied
Study Locations (4)
Florida
- Moffit Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
Pennsylvania
- St Luke's University Hospital and Health Network - Bethlehem
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-09-17 |
What the finished NCT01986712 record still lists
NCT01986712 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT01986712 reports a single indexed study location in Florida, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01986712 about?
NCT01986712 is a clinical study titled "A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma". To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
What is the current status of trial NCT01986712?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2013-12. Estimated completion is 2019-09-17.
What conditions does trial NCT01986712 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT01986712?
This trial is sponsored by St. Luke's Hospital and Health Network, Pennsylvania, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986712 being conducted?
This trial has 4 study locations across Florida, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01986712's enrollment target sits among peer trials
50 163rd of 266 higher than 99 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia